Dr Laura Waters
@drlaurajwaters.bsky.social
NHS GUM/HIV doc @CNWLNHS | Honorary Assoc Professor @UCLGlobalHealth | @[email protected] founder | ex BHIVA chair | NSA HIV @NHSEngland |
@RCPhysicians PIO | BASHH patient & public panel chair | she/her | @iasociety GC | Campari | Humanism
@RCPhysicians PIO | BASHH patient & public panel chair | she/her | @iasociety GC | Campari | Humanism
Linda Gail Bekker highlighted the critical importance of oral loading with lenacapavir. Missing it significantly delays (to 28 days) the time taken to achieve target concentrations which are reached by day 2 with loading
#IAS2025
@iasociety.bsky.social
#IAS2025
@iasociety.bsky.social
July 17, 2025 at 9:48 AM
Linda Gail Bekker highlighted the critical importance of oral loading with lenacapavir. Missing it significantly delays (to 28 days) the time taken to achieve target concentrations which are reached by day 2 with loading
#IAS2025
@iasociety.bsky.social
#IAS2025
@iasociety.bsky.social
July 17, 2025 at 8:55 AM
Impact of PEPFAR cuts on HIV care in Mozambique #IAS2025 with 3rd highest no of PWH & 2nd highest new diagnoses, 67% of funding from PEPFAR in 2022.
- 14% reduction in ART initiations
- 39% increase in ART interruption
- reduced VL testing & viral suppression, esp children
@iasociety.bsky.social
- 14% reduction in ART initiations
- 39% increase in ART interruption
- reduced VL testing & viral suppression, esp children
@iasociety.bsky.social
July 16, 2025 at 1:16 PM
Impact of PEPFAR cuts on HIV care in Mozambique #IAS2025 with 3rd highest no of PWH & 2nd highest new diagnoses, 67% of funding from PEPFAR in 2022.
- 14% reduction in ART initiations
- 39% increase in ART interruption
- reduced VL testing & viral suppression, esp children
@iasociety.bsky.social
- 14% reduction in ART initiations
- 39% increase in ART interruption
- reduced VL testing & viral suppression, esp children
@iasociety.bsky.social
#IAS2025 first ever lenacapavir PrEP implementation study will be in Brazil! Will include a mobile PrEP unit in Sao Paolo to best reach communities who will benefit
@iasociety.bsky.social
@iasociety.bsky.social
July 16, 2025 at 11:05 AM
#IAS2025 first ever lenacapavir PrEP implementation study will be in Brazil! Will include a mobile PrEP unit in Sao Paolo to best reach communities who will benefit
@iasociety.bsky.social
@iasociety.bsky.social
At the IAS members meeting with a wondrous panel (see pic). I'm finding the discussions about funding & the struggles people experience trying to fund their attendance really emotive. This will be increasingly challenging in the future & I wish I had a solution
#ias2025
#ias2025
July 16, 2025 at 9:29 AM
At the IAS members meeting with a wondrous panel (see pic). I'm finding the discussions about funding & the struggles people experience trying to fund their attendance really emotive. This will be increasingly challenging in the future & I wish I had a solution
#ias2025
#ias2025
The much anticipated DO-IT trial shows no impact of switch from TAF + INSTI to DOR (with TAF or TDF) on weight in people with obesity. Considering switching ART only to address weight change? DON'T DO-IT.....
#IAS2025
@iasociety.bsky.social
#IAS2025
@iasociety.bsky.social
July 15, 2025 at 3:12 PM
The much anticipated DO-IT trial shows no impact of switch from TAF + INSTI to DOR (with TAF or TDF) on weight in people with obesity. Considering switching ART only to address weight change? DON'T DO-IT.....
#IAS2025
@iasociety.bsky.social
#IAS2025
@iasociety.bsky.social
The TECAIN Study (tricholoacetic acid vs electrocautery for AIN treatment in people with HIV) at 24W showed TCA non-inferior to ECA.
#IAS2027
@iasociety.bsky.social
@tristanjbarber.bsky.social
#IAS2027
@iasociety.bsky.social
@tristanjbarber.bsky.social
July 15, 2025 at 2:46 PM
The TECAIN Study (tricholoacetic acid vs electrocautery for AIN treatment in people with HIV) at 24W showed TCA non-inferior to ECA.
#IAS2027
@iasociety.bsky.social
@tristanjbarber.bsky.social
#IAS2027
@iasociety.bsky.social
@tristanjbarber.bsky.social
IMPALA results at #IAS2025
1 incident HBV infection in the CAB/RPV arm
No evidence of HBV reactivation (note people with detectable cAb but sAb <10 were excluded)
@iasociety.bsky.social @profchloeorkin.bsky.social @tristanjbarber.bsky.social
1 incident HBV infection in the CAB/RPV arm
No evidence of HBV reactivation (note people with detectable cAb but sAb <10 were excluded)
@iasociety.bsky.social @profchloeorkin.bsky.social @tristanjbarber.bsky.social
July 15, 2025 at 2:42 PM
IMPALA results at #IAS2025
1 incident HBV infection in the CAB/RPV arm
No evidence of HBV reactivation (note people with detectable cAb but sAb <10 were excluded)
@iasociety.bsky.social @profchloeorkin.bsky.social @tristanjbarber.bsky.social
1 incident HBV infection in the CAB/RPV arm
No evidence of HBV reactivation (note people with detectable cAb but sAb <10 were excluded)
@iasociety.bsky.social @profchloeorkin.bsky.social @tristanjbarber.bsky.social
Rosemary Mburu #ias2025
"Science is not just data! It is DIGNITY.
Investment in people is not just nice to have, it's creating powerful agents for change.
RESILIENCE MUST BE MET WITH RESPECT
@iasociety.bsky.social
"Science is not just data! It is DIGNITY.
Investment in people is not just nice to have, it's creating powerful agents for change.
RESILIENCE MUST BE MET WITH RESPECT
@iasociety.bsky.social
July 14, 2025 at 3:42 PM
Rosemary Mburu #ias2025
"Science is not just data! It is DIGNITY.
Investment in people is not just nice to have, it's creating powerful agents for change.
RESILIENCE MUST BE MET WITH RESPECT
@iasociety.bsky.social
"Science is not just data! It is DIGNITY.
Investment in people is not just nice to have, it's creating powerful agents for change.
RESILIENCE MUST BE MET WITH RESPECT
@iasociety.bsky.social
Beatriz Grinszetjn
Opens #ias2025!
While she can't provide a recipe for success in current climate, there are key factors
1. EVIDENCE
2. SOLIDARITY
3. TRUTH
Let us make the most of our time together at the conference to "reaffirm, refocus & rebuild!"
@iasociety.bsky.social
Opens #ias2025!
While she can't provide a recipe for success in current climate, there are key factors
1. EVIDENCE
2. SOLIDARITY
3. TRUTH
Let us make the most of our time together at the conference to "reaffirm, refocus & rebuild!"
@iasociety.bsky.social
July 14, 2025 at 3:32 PM
Beatriz Grinszetjn
Opens #ias2025!
While she can't provide a recipe for success in current climate, there are key factors
1. EVIDENCE
2. SOLIDARITY
3. TRUTH
Let us make the most of our time together at the conference to "reaffirm, refocus & rebuild!"
@iasociety.bsky.social
Opens #ias2025!
While she can't provide a recipe for success in current climate, there are key factors
1. EVIDENCE
2. SOLIDARITY
3. TRUTH
Let us make the most of our time together at the conference to "reaffirm, refocus & rebuild!"
@iasociety.bsky.social
New @who.int postnatal prophylaxis guidelines :
Infants at ow-risk
- preferred: 6W NVP for 6W
- alternative: DTG or 3TC for 6W
Infants at high-risk
- ABC + 3TC + DTG for 6W
- plus extended PNP during breastfeeding (nevirapine preferred, DTG or 3TC alternatives)
#IAS2025
@iasociety.bsky.social
Infants at ow-risk
- preferred: 6W NVP for 6W
- alternative: DTG or 3TC for 6W
Infants at high-risk
- ABC + 3TC + DTG for 6W
- plus extended PNP during breastfeeding (nevirapine preferred, DTG or 3TC alternatives)
#IAS2025
@iasociety.bsky.social
July 14, 2025 at 11:38 AM
New @who.int postnatal prophylaxis guidelines :
Infants at ow-risk
- preferred: 6W NVP for 6W
- alternative: DTG or 3TC for 6W
Infants at high-risk
- ABC + 3TC + DTG for 6W
- plus extended PNP during breastfeeding (nevirapine preferred, DTG or 3TC alternatives)
#IAS2025
@iasociety.bsky.social
Infants at ow-risk
- preferred: 6W NVP for 6W
- alternative: DTG or 3TC for 6W
Infants at high-risk
- ABC + 3TC + DTG for 6W
- plus extended PNP during breastfeeding (nevirapine preferred, DTG or 3TC alternatives)
#IAS2025
@iasociety.bsky.social
New World Health Organization guidelines recommend darunavir as preferred PI and new appearance for LA-CAB/RPV as a switch option for people who are virally suppressed.
#IAS2027
@iasociety.bsky.social @who.int @tristanjbarber.bsky.social
#IAS2027
@iasociety.bsky.social @who.int @tristanjbarber.bsky.social
July 14, 2025 at 11:25 AM
New World Health Organization guidelines recommend darunavir as preferred PI and new appearance for LA-CAB/RPV as a switch option for people who are virally suppressed.
#IAS2027
@iasociety.bsky.social @who.int @tristanjbarber.bsky.social
#IAS2027
@iasociety.bsky.social @who.int @tristanjbarber.bsky.social
@who.int guidelines launch at #IAS2025 includes the just released guidelines on LEN PrEP including recommendation to use HIV rapid tests, NAAT too slow & expensive....
iris.who.int/bitstream/ha...
@tristanjbarber.bsky.social
iris.who.int/bitstream/ha...
@tristanjbarber.bsky.social
July 14, 2025 at 11:16 AM
@who.int guidelines launch at #IAS2025 includes the just released guidelines on LEN PrEP including recommendation to use HIV rapid tests, NAAT too slow & expensive....
iris.who.int/bitstream/ha...
@tristanjbarber.bsky.social
iris.who.int/bitstream/ha...
@tristanjbarber.bsky.social
Mitchell Warren of AVAC shares data, based on many assumptions, of potential injectable PrEP use in 2026 based on 2024 oral uptake & preference data.
And the ways forward.....prioritise, prioritise, prioritise (sorry, I changed the spelling 😘)
#IAS2025
And the ways forward.....prioritise, prioritise, prioritise (sorry, I changed the spelling 😘)
#IAS2025
July 14, 2025 at 7:48 AM
Mitchell Warren of AVAC shares data, based on many assumptions, of potential injectable PrEP use in 2026 based on 2024 oral uptake & preference data.
And the ways forward.....prioritise, prioritise, prioritise (sorry, I changed the spelling 😘)
#IAS2025
And the ways forward.....prioritise, prioritise, prioritise (sorry, I changed the spelling 😘)
#IAS2025
We are at an absolutely critical point in the HIV response which is why the @iasociety.bsky.social conference in Kigali so so very important. And when LISTENING is more important than ever, the live translation feature for the main sessions is particularly welcome....well done IAS #IAS2025
July 12, 2025 at 9:42 AM
We are at an absolutely critical point in the HIV response which is why the @iasociety.bsky.social conference in Kigali so so very important. And when LISTENING is more important than ever, the live translation feature for the main sessions is particularly welcome....well done IAS #IAS2025
Outstanding presentation on gender affirming care for adults in the UK from Alison Berner #bashh2025
The 2 screenshots provide invaluable advice, & until new NHSE guidance is produced, the 2019 advice applies
@bashhuk.bsky.social
The 2 screenshots provide invaluable advice, & until new NHSE guidance is produced, the 2019 advice applies
@bashhuk.bsky.social
June 10, 2025 at 11:34 AM
Outstanding presentation on gender affirming care for adults in the UK from Alison Berner #bashh2025
The 2 screenshots provide invaluable advice, & until new NHSE guidance is produced, the 2019 advice applies
@bashhuk.bsky.social
The 2 screenshots provide invaluable advice, & until new NHSE guidance is produced, the 2019 advice applies
@bashhuk.bsky.social
FFFS. Maybe I'm just particularly grumpy & tired today but stop saying that PEOPLE FAILED. Their treatment failed. Especially when they are on injectables and had all their injections on time. I'm literally flinching each time I hear it.
@peoplefirstcharter.bsky.social
#CROI2025
@peoplefirstcharter.bsky.social
#CROI2025
March 12, 2025 at 11:53 PM
FFFS. Maybe I'm just particularly grumpy & tired today but stop saying that PEOPLE FAILED. Their treatment failed. Especially when they are on injectables and had all their injections on time. I'm literally flinching each time I hear it.
@peoplefirstcharter.bsky.social
#CROI2025
@peoplefirstcharter.bsky.social
#CROI2025
Sobering talk from an excellent Jeremy Nel on global implications of INSTI resistance.
"Nuisance for HIC but profound challenges for LMIC" - so true
#CROI2025
"Nuisance for HIC but profound challenges for LMIC" - so true
#CROI2025
March 12, 2025 at 11:39 PM
Sobering talk from an excellent Jeremy Nel on global implications of INSTI resistance.
"Nuisance for HIC but profound challenges for LMIC" - so true
#CROI2025
"Nuisance for HIC but profound challenges for LMIC" - so true
#CROI2025
More daily DOR/ISL from @profchloeorkin.bsky.social #CROI2025
This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic.
Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV
This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic.
Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV
March 12, 2025 at 8:06 PM
More daily DOR/ISL from @profchloeorkin.bsky.social #CROI2025
This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic.
Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV
This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic.
Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV
More daily DOR/ISL from @profchloeorkin.bsky.social #CROI2025
This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic.
Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV
This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic.
Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV
March 12, 2025 at 8:02 PM
More daily DOR/ISL from @profchloeorkin.bsky.social #CROI2025
This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic.
Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV
This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic.
Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV
#CROI2025 continued Biktarvy vs switch to daily ISL/DOR with ISL at safer lower dose of 0.25mg.
ISL/DOR non-inferior at W48, 2 CVFs, no RAMs, both resuppressed in Biktarvy, no diff in CD4/TLC.
2 cases acute HBV in cAb- & sAb- people
ISL/DOR non-inferior at W48, 2 CVFs, no RAMs, both resuppressed in Biktarvy, no diff in CD4/TLC.
2 cases acute HBV in cAb- & sAb- people
March 12, 2025 at 7:58 PM
#CROI2025 continued Biktarvy vs switch to daily ISL/DOR with ISL at safer lower dose of 0.25mg.
ISL/DOR non-inferior at W48, 2 CVFs, no RAMs, both resuppressed in Biktarvy, no diff in CD4/TLC.
2 cases acute HBV in cAb- & sAb- people
ISL/DOR non-inferior at W48, 2 CVFs, no RAMs, both resuppressed in Biktarvy, no diff in CD4/TLC.
2 cases acute HBV in cAb- & sAb- people
Ph2b EMBRACE #CROI2025 Q4M N6LS + QM CAB bNAb SC vs IM vs continued oral in VS ppl.
4CVFs on N6LS/CAB, 1 with CAB RAMs, 3 with N6LS resistance.
IV will be going forwards
4CVFs on N6LS/CAB, 1 with CAB RAMs, 3 with N6LS resistance.
IV will be going forwards
March 12, 2025 at 7:49 PM
Ph2b EMBRACE #CROI2025 Q4M N6LS + QM CAB bNAb SC vs IM vs continued oral in VS ppl.
4CVFs on N6LS/CAB, 1 with CAB RAMs, 3 with N6LS resistance.
IV will be going forwards
4CVFs on N6LS/CAB, 1 with CAB RAMs, 3 with N6LS resistance.
IV will be going forwards
96W CARES CAB/RPV. Efficacy remains high and non-inferior vs continued oral ART (97% <50)
4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced.
Great results.
4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced.
Great results.
March 12, 2025 at 7:40 PM
96W CARES CAB/RPV. Efficacy remains high and non-inferior vs continued oral ART (97% <50)
4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced.
Great results.
4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced.
Great results.
ACTG5418: Tecovirimat vs PBO clade 2 mpox n=344 #CROI2025
Study stopped early due to DSMB futility analysis (unbeknownst to study team?!)
25% recruited remotely
HR for clinical resolution....0.98 (o.74-1.31) & no diff in subgroup analysis incl symptom duration. No difference in viral clearance/pain
Study stopped early due to DSMB futility analysis (unbeknownst to study team?!)
25% recruited remotely
HR for clinical resolution....0.98 (o.74-1.31) & no diff in subgroup analysis incl symptom duration. No difference in viral clearance/pain
March 12, 2025 at 7:30 PM
ACTG5418: Tecovirimat vs PBO clade 2 mpox n=344 #CROI2025
Study stopped early due to DSMB futility analysis (unbeknownst to study team?!)
25% recruited remotely
HR for clinical resolution....0.98 (o.74-1.31) & no diff in subgroup analysis incl symptom duration. No difference in viral clearance/pain
Study stopped early due to DSMB futility analysis (unbeknownst to study team?!)
25% recruited remotely
HR for clinical resolution....0.98 (o.74-1.31) & no diff in subgroup analysis incl symptom duration. No difference in viral clearance/pain
#CROI2025
19-43% C19 household transmission rates.
SCORPIO randomised >2300 contacts to ensitrelvir vs PBO (78% enrolled within 48h of symptom onset in index case, 37% of whom were at high risk of complications.
67% reduction in C19 acquisition 1 at day 10!! 76% if high risk!
WOW.
19-43% C19 household transmission rates.
SCORPIO randomised >2300 contacts to ensitrelvir vs PBO (78% enrolled within 48h of symptom onset in index case, 37% of whom were at high risk of complications.
67% reduction in C19 acquisition 1 at day 10!! 76% if high risk!
WOW.
March 12, 2025 at 7:23 PM
#CROI2025
19-43% C19 household transmission rates.
SCORPIO randomised >2300 contacts to ensitrelvir vs PBO (78% enrolled within 48h of symptom onset in index case, 37% of whom were at high risk of complications.
67% reduction in C19 acquisition 1 at day 10!! 76% if high risk!
WOW.
19-43% C19 household transmission rates.
SCORPIO randomised >2300 contacts to ensitrelvir vs PBO (78% enrolled within 48h of symptom onset in index case, 37% of whom were at high risk of complications.
67% reduction in C19 acquisition 1 at day 10!! 76% if high risk!
WOW.